PDF herunterladen
Semin Musculoskelet Radiol 2010; 14(1): 086-094
DOI: 10.1055/s-0030-1248708
© Thieme Medical Publishers

Targeted Contrast Agents—an Adjunct to Whole-Body Imaging: Current Concepts

Paul Foran1 , Ferdia Bolster1 , Ian Crosbie1 , Peter MacMahon2 , Richard O'Kennedy3 , Stephen J. Eustace1 , 2 , 4
  • 1Department of Radiology, Mater Misericordiae University Hospital, Dublin, Ireland
  • 2Department of Radiology, Cappagh National Orthopaedic Hospital, Finglas, Dublin, Ireland
  • 3School of Biotechnology and National Centre for Sensor Research, Dublin City University, Dublin, Ireland
  • 4Department of Radiology, University College Dublin, Dublin, Ireland
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
12. März 2010 (online)

Auch verfügbar auf
    Lizenzen und Reprints

ABSTRACT

This article reviews the potential use of a combination of whole-body imaging and targeted contrast agents in improving diagnostics, with a particular focus on oncology imaging. It looks at the rationale for nanoparticles and their development as targeted contrast agents. It subsequently describes many of the advances made thus far in developing tissue-specific contrast agents capable of targeting tumors that combined with whole-body imaging may enable superior cancer detection and characterization.

KEYWORDS

MRI - liposomes - nanoparticles - receptors

REFERENCES

  • 1 Johnston C, Brennan S, Ford S, Eustace S. Whole body MR imaging: applications in oncology.  Eur J Surg Oncol. 2006;  32 239-246
    CrossrefPubMedGoogle Scholar
  • 2 Mulder W JM, Strijkers G J, Griffioen A W et al.. A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets.  Bioconjug Chem. 2004;  15(4) 799-806
    CrossrefPubMedGoogle Scholar
  • 3 Aime S, Dastrù W, Crich S G, Gianolio E, Mainero V. Innovative magnetic resonance imaging diagnostic agents based on paramagnetic Gd(III) complexes.  Biopolymers. 2002;  66(6) 419-428
    CrossrefPubMedGoogle Scholar
  • 4 Caravan P, Ellison J J, McMurry T J, Lauffer R B. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications.  Chem Rev. 1999;  99(9) 2293-2352
    CrossrefPubMedGoogle Scholar
  • 5 Weinmann H J, Ebert W, Misselwitz B, Schmitt-Willich H. Tissue-specific MR contrast agents.  Eur J Radiol. 2003;  46(1) 33-44
    CrossrefPubMedGoogle Scholar
  • 6 Gupta H, Weissleder R. Targeted contrast agents in MR imaging.  Magn Reson Imaging Clin N Am. 1996;  4(1) 171-184
    PubMedGoogle Scholar
  • 7 Strijkers G J, Mulder W J, van Heeswijk R B et al.. Relaxivity of liposomal paramagnetic MRI contrast agents.  MAGMA. 2005;  18(4) 186-192
    CrossrefPubMedGoogle Scholar
  • 8 Gløgård C, Stensrud G, Hovland R, Fossheim S L, Klaveness J. Liposomes as carriers of amphiphilic gadolinium chelates: the effect of membrane composition on incorporation efficacy and in vitro relaxivity.  Int J Pharm. 2002;  233(1-2) 131-140
    CrossrefPubMedGoogle Scholar
  • 9 Huang S K, Mayhew E, Gilani S, Lasic D D, Martin F J, Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.  Cancer Res. 1992;  52(24) 6774-6781
    PubMedGoogle Scholar
  • 10 Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS.  J Control Release. 2001;  74 47-61
    CrossrefPubMedGoogle Scholar
  • 11 Ishida O, Maruyama K, Tanahashi H et al.. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo.  Pharm Res. 2001;  18(7) 1042-1048
    CrossrefPubMedGoogle Scholar
  • 12 Seymour L W. Passive tumor targeting of soluble macromolecules and drug conjugates.  Crit Rev Ther Drug Carrier Syst. 1992;  9(2) 135-187
    PubMedGoogle Scholar
  • 13 Kairemo K, Erba P, Bergstrom K, Pauwels E KJ. Nanoparticles in cancer.  Curr Radiopharm. 2008;  1 30-36
    PubMedGoogle Scholar
  • 14 Park J W, Hong K, Kirpotin D B et al.. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.  Clin Cancer Res. 2002;  8(4) 1172-1181
    PubMedGoogle Scholar
  • 15 Yang Z, Yang M, Xiahou G, Peng J, Zhang J J. Targeted delivery of insulin-modified immunoliposomes in vivo.  Liposome Res. 2009;  1-6
    PubMedGoogle Scholar
  • 16 Chang D K, Lin C T, Wu C H, Wu H C. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer.  PLoS One. 2009;  4(1) e4171
    CrossrefPubMedGoogle Scholar
  • 17 Sihorkar V, Vyas S PJ. Potential of polysaccharide anchored liposomes in drug delivery, targeting and immunization.  J Pharm Pharmaceut Sci. 2001;  4(2) 138-158
    PubMedGoogle Scholar
  • 18 Wang X, Yang L, Chen Z G, Shin D M. Application of nanotechnology in cancer therapy and imaging.  CA Cancer J Clin. 2008;  58 97-110
    CrossrefPubMedGoogle Scholar
  • 19 Park J W, Hong K, Kirpotin D B, Papahadjopoulos D, Benz C C. Immunoliposomes for cancer treatment.  Adv Pharmacol. 1997;  40 399-435
    PubMedGoogle Scholar
  • 20 Roth P, Hammer C, Piguet A C, Ledermann M, Dufour J F, Waelti E. Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target VEGFR-2.  J Drug Target. 2007;  15(9) 623-631
    CrossrefPubMedGoogle Scholar
  • 21 Sokolov K, Aaron J, Kumar S et al.. Molecular imaging of carcinogenesis with immuno-targeted nanoparticles.  Conf Proc IEEE Eng Med Biol Soc. 2004;  7 5292-5295
    PubMedGoogle Scholar
  • 22 Hilgenbrink A R, Low P SJ. Folate receptor-mediated drug targeting: from therapeutics to diagnostics.  J Pharm Sci. 2005;  94 2135-2146
    CrossrefPubMedGoogle Scholar
  • 23 Yoo H S, Park T GJ. Folate receptor targeted biodegradable polymeric doxorubicin micelles.  J Control Release. 2004;  96 276-283
    PubMedGoogle Scholar
  • 24 Sahoo S K, Ma W, Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer.  Int J Cancer. 2004;  112(2) 335-340
    CrossrefPubMedGoogle Scholar
  • 25 Iakoubov L Z, Torchilin V P. A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice.  Oncol Res. 1997;  9(8) 439-446
    PubMedGoogle Scholar
  • 26 Erdogan S, Roby A, Sawant R, Hurley J, Torchilin V PJ. Gadolinium-loaded polychelating polymer-containing cancer cell-specific immunoliposomes.  Liposome Res. 2006;  16 45-55
    PubMedGoogle Scholar
  • 27 Erdogan S, Medarova Z O, Roby A, Moore A, Torchilin V PJ. Enhanced tumor MR imaging with gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes.  J Magn Reson Imaging. 2008;  27(3) 574-580
    CrossrefPubMedGoogle Scholar
  • 28 Ito A, Shinkai M, Honda H, Kobayashi T. Medical application of functionalized magnetic nanoparticles.  Biosci Bioeng. 2005;  100(1) 1-11
    CrossrefPubMedGoogle Scholar
  • 29 Suzuki M, Honda H, Kobayashi T, Wakabayashi T, Yoshida J, Takahashi M. Development of a target-directed magnetic resonance contrast agent using monoclonal antibody-conjugated magnetic particles.  Noshuyo Byori. 1996;  13 127-132
    PubMedGoogle Scholar
  • 30 Baio G, Fabbi M, Salvi S et al.. Two-step in vivo tumor targeting by biotin-conjugated antibodies and superparamagnetic nanoparticles assessed by magnetic resonance imaging at 1.5 T.  Mol Imaging Biol. 2009; 
    PubMedGoogle Scholar
  • 31 Artemov D, Mori N, Okollie B, Bhujwalla Z M. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles.  Magn Reson Med. 2003;  49(3) 403-408
    CrossrefPubMedGoogle Scholar
  • 32 Artemov D, Mori N, Ravi R, Bhujwalla Z M. Magnetic resonance molecular imaging of the HER-2/neu receptor.  Cancer Res. 2003;  63(11) 2723-2727
    PubMedGoogle Scholar
  • 33 Kramer-Marek G, Kiesewetter D O, Martiniova L, Jagoda E, Lee S B, Capala J. [18F]FBEM-Z(HER2:342)-Affibody molecule—a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography.  Eur J Nucl Med Mol Imaging. 2008;  35(5) 1008-1018
    CrossrefPubMedGoogle Scholar
  • 34 Kramer-Marek G, Kiesewetter D O, Capala J J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules.  J Nucl Med. 2009;  50(7) 1131-1139
    CrossrefPubMedGoogle Scholar
  • 35 Sundaresan G, Yazaki P J, Shively J E et al.. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.  J Nucl Med. 2003;  44(12) 1962-1969
    PubMedGoogle Scholar
  • 36 Neufeld G, Cohen T, Gitay-Goren H et al.. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants.  Cancer Metastasis Rev. 1996;  15(2) 153-158
    CrossrefPubMedGoogle Scholar
  • 37 Kerbel R S. Tumor angiogenesis: past, present and the near future.  Carcinogenesis. 2000;  21(3) 505-515
    CrossrefPubMedGoogle Scholar
  • 38 Collingridge D R, Carroll V A, Glaser M et al.. The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography.  Cancer Res. 2002;  62(20) 5912-5919
    PubMedGoogle Scholar

Paul ForanM.B. 

Department of Radiology, Mater Misericordiae University Hospital

Eccles St., Dublin 7, Ireland

eMail: paulforan2006@gmail.com

      >